Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling
Barrie Cohen(Rutgers, The State University of New Jersey), Jonathan Gill(Albert Einstein College of Medicine), Richard Görlick(Albert Einstein College of Medicine), Michael Roth(The University of Texas MD Anderson Cancer Center), David S. Geller(Albert Einstein College of Medicine), Katherine A. Janeway(Dana-Farber Cancer Institute), Stacy W. Gray(Dana-Farber Cancer Institute), Bang H. Hoang(Albert Einstein College of Medicine), Jonathan M. Marron(Dana-Farber/Boston Children's Cancer and Blood Disorders Center)
Cited by 23
Related Papers
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|981
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Institutional implementation of clinical tumor profiling on an unselected cancer population
|JCI Insight|2016|447
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419